Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S125000, C548S136000, C548S250000, C548S262200, C548S364100, C514S361000, C514S363000, C514S364000, C514S403000
Reexamination Certificate
active
07875647
ABSTRACT:
A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
REFERENCES:
patent: 5925768 (1999-07-01), Barth et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6825209 (2004-11-01), Thomas et al.
patent: 7632852 (2009-12-01), Barth et al.
patent: 2003/0199536 (2003-10-01), Thomas et al.
patent: 2006/0030563 (2006-02-01), Makriyannis et al.
patent: 2006/0100208 (2006-05-01), Makriyannis et al.
patent: 2007/0021486 (2007-01-01), Barth et al.
patent: WO 00/46209 (2000-08-01), None
patent: WO 2005/073197 (2005-08-01), None
patent: WO 2005/084652 (2005-09-01), None
patent: WO 2006/087480 (2006-08-01), None
patent: WO 2006/133926 (2006-12-01), None
patent: WO 2007/046550 (2007-04-01), None
Maslivets et al (1990): STN International HCAPLUS database, (Columbus, Ohio), Accession No.: 1990:55776.
Barth et al (2006): STN International HCAPLUS database, (Columbus, Ohio), Accession No.: 2006:841713.
Lan, R., et al., :Structure-Activity Relationships of Pyrazole Derivative as Cannabinoid Receptor Antagonists, J. Med. Chem. 1999, 42, 769-776.
Shim, J.Y., et al., “Molecular Interaction of the Antagonist N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1Cannabinoid Receptor,” J. Med. Chem. 2002, 45, 1447-1459.
Francisco, M.E., et al., Synthesis and Structure—Activity Relationship of Amide and Hydrazide Analogues of the Cannabinoid CB1Receptor AntagonistN-(Piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dicholorphenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716), J. Med. Chem. 2002, 45, 2708-2719.
Katosh-Rouse, R., et al., “Synthesis, Structure-Activity Relationship, and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity,” J. Med. Chem. 2003, 46, 642-645.
Ruiu, S., et al., “Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1Cannabinoid Receptor,” J. Pharmacology and Experimental Therapeutics, Mar. 2003, 306, 1, 363-370.
Rinaldi-Carmona, M., et al., “SR147778[5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization,” J. Pharmacology And Experimental Therapeutics, May 3, 2004, 310, 3, 905-914.
Chen, J-Z., et al., “3D-QSAR Studies of Arylpyrazole Antagonists of Cannabinoid Receptor Subtypes CB1 and CB2. A Combined NMR an CoMFA Approach,” J. Medicinal Chem., Depart. Of Pharmaceutical & Pharmacological Sciences, Univ. of Houston, Jul. 12, 2005.
Muccioli G.G., et al., “Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptor,” Current Medicial Chem., 2005, 12, 1361-1394.
Lange, J.H.M. et al., “Medicinal chemistry strategies to CB1cannabinoid receptor antagonists,” DDT, 10, May 10, 2005, 693-702.
Alekseeva, O.O., “Synthesis of novel 5-substituted pyrazole derivatives as cannabinoid antagonists,” Tetrahedron Letters, 2005, 46, 2159-2161.
Ahn Kwang-Woo
Chang Chong-Hwan Jonathan
Jung Myung Eun
Kang Suk Youn
Kim Jeong Min
Green Cross Corporation
Shameem Golam M
Sughrue & Mion, PLLC
LandOfFree
Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665581